Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.
Hepatocellular carcinoma
LncRNAs
Mitoepigenetics
Natural products
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
27 Oct 2024
27 Oct 2024
Historique:
received:
27
08
2024
accepted:
07
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is a leading liver cancer that significantly impacts global life expectancy and remains challenging to treat due to often late diagnoses. Despite advances in treatment, the prognosis is still poor, especially in advanced stages. Studies have pointed out that investigations into the molecular mechanisms underlying HCC, including mitochondrial dysfunction and epigenetic regulators, are potentially important targets for diagnosis and therapy. Mitoepigenetics, or the epigenetic modifications of mitochondrial DNA, have drawn wide attention for their role in HCC progression. Besides, molecular biomarkers such as mitochondrial DNA alterations and non-coding RNAs showed early diagnosis and prognosis potential. Additionally, natural compounds like alkaloids, resveratrol, curcumin, and flavonoids show promise in HCC show promise in modulating mitochondrial and epigenetic pathways involved in cancer-related processes. This review discusses how mitochondrial dysfunction and epigenetic modifications, especially mitoepigenetics, influence HCC and delves into the potential of natural products as new adjuvant treatments against HCC.
Identifiants
pubmed: 39465473
doi: 10.1007/s12032-024-02538-8
pii: 10.1007/s12032-024-02538-8
doi:
Substances chimiques
Biological Products
0
DNA, Mitochondrial
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
302Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
pubmed: 38572751
doi: 10.3322/caac.21834
Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chem Biol Lett. 2023;10(1):451.
Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–606.
pubmed: 36208844
pmcid: 9670241
doi: 10.1016/j.jhep.2022.08.021
Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Mendez-Sanchez N, Yuen MF, Hwang JP. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2018;38:262–79.
pubmed: 30231359
doi: 10.1200/EDBK_200939
Asafo-Agyei KO SH, Hepatocellular carcinoma, StatPearls. 2023.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.
pubmed: 33479224
doi: 10.1038/s41572-020-00240-3
Hsu CC, Lee HC, Wei YH. Mitochondrial DNA alterations and mitochondrial dysfunction in the progression of hepatocellular carcinoma. World J Gastroenterol. 2013;19(47):8880–6.
pubmed: 24379611
pmcid: 3870539
doi: 10.3748/wjg.v19.i47.8880
Infantino V, Dituri F, Convertini P, Santarsiero A, Palmieri F, Todisco S, Mancarella S, Giannelli G, Iacobazzi V. (2019) Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochim et Biophys Acta (BBA): Mol Basis Dis. 1865;1:38–47.
Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene. 2006;25(34):4647–62.
pubmed: 16892079
doi: 10.1038/sj.onc.1209607
Lee HC, Wei YH. Mitochondrial DNA instability and metabolic shift in human cancers. Int J Mol Sci. 2009;10(2):674–701.
pubmed: 19333428
pmcid: 2660656
doi: 10.3390/ijms10020674
Lozano-Rosas MG, Chávez E, Aparicio-Cadena AR, Velasco-Loyden G, Sánchez VCD. Mitoepigenetics and hepatocellular carcinoma. Hepatoma Res. 2018;4:19.
doi: 10.20517/2394-5079.2018.48
Liu Y, Chen C, Wang X, Sun Y, Zhang J, Chen J, Shi Y. An epigenetic role of mitochondria in cancer. Cells. 2022;11(16):2518.
pubmed: 36010594
pmcid: 9406960
doi: 10.3390/cells11162518
Asma MA, Hussien AE. Natural products and hepatocellular carcinoma: a review. Hepatoma Res. 2015;1:119–24.
doi: 10.4103/2394-5079.167379
Li Y, Li H, He Q, Yang X. Potential of compounds originating from the nature to act in hepatocellular carcinoma therapy by targeting the tumor immunosuppressive microenvironment: a review. Molecules. 2022;28(1):195.
pubmed: 36615387
pmcid: 9822070
doi: 10.3390/molecules28010195
Gao J, Yin Z, Wu Z, Sheng Z, Ma C, Chen R, Zhang X, Tang K, Fei J, Cao Z. Probing synergistic targets by natural compounds for hepatocellular carcinoma. Front Cell Dev Biol. 2021;9:715762.
pubmed: 34395446
pmcid: 8355820
doi: 10.3389/fcell.2021.715762
Mohamed AH, Ezzeldein SME-D, Mosaad AA-W. Effects of natural compounds in treatment and prevention of hepatotoxicity and hepatocellular carcinoma. Hepatoma Res. 2015;1:111–8.
doi: 10.4103/2394-5079.167378
Zheng Y, Zhang W, Xu L, Zhou H, Yuan M, Xu H. Recent progress in understanding the action of natural compounds at novel therapeutic drug targets for the treatment of liver cancer. Front Oncol. 2021;11:795548.
pubmed: 35155196
doi: 10.3389/fonc.2021.795548
El-Nakeep S. Molecular and genetic markers in hepatocellular carcinoma: in silico analysis to clinical validation (current limitations and future promises). World J Gastrointest Pathophysiol. 2022;13(1):1–1.
pubmed: 35116176
pmcid: 8788164
doi: 10.4291/wjgp.v13.i1.1
Chen F, Wang J, Wu Y, Gao Q, Zhang S. Potential biomarkers for liver cancer diagnosis based on multi-omics strategy. Front Oncol. 2022;12:822449.
pubmed: 35186756
pmcid: 8851237
doi: 10.3389/fonc.2022.822449
Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol. 2015;2(4):371–371.
pubmed: 26617981
pmcid: 4662420
doi: 10.2217/hep.15.26
Kancherla V, Abdullazade S, Matter MS, Lanzafame M, Quagliata L, Roma G, Hoshida Y, Terracciano LM, Ng CKY, Piscuoglio S. Genomic analysis revealed new oncogenic signatures in TP53-mutant hepatocellular carcinoma. Front Genet. 2018;9:2.
pubmed: 29456550
pmcid: 5801302
doi: 10.3389/fgene.2018.00002
Maravelia P, Silva DN, Rovesti G, Chrobok M, Stål P, Lu YC, Pasetto A. Liquid biopsy in hepatocellular carcinoma: opportunities and challenges for immunotherapy. Cancers. 2021;13(17):4334–4334.
pubmed: 34503144
pmcid: 8431414
doi: 10.3390/cancers13174334
Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50(2):136–42.
pubmed: 21229610
doi: 10.1002/mc.20712
Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol: WJG. 2015;21(37):10573–10573.
pubmed: 26457017
pmcid: 4588079
doi: 10.3748/wjg.v21.i37.10573
Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA. The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med. 2017;15(1):1–10.
doi: 10.1186/s12967-017-1325-2
Adeniji N, Dhanasekaran R. Current and emerging tools for hepatocellular carcinoma surveillance. Hepatol Commun. 2021;5(12):1972–1972.
pubmed: 34533885
pmcid: 8631096
doi: 10.1002/hep4.1823
Marquardt JU, Andersen JB. Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepatic Oncology. 2015;2(1):79–79.
pubmed: 26257864
pmcid: 4523883
doi: 10.2217/hep.14.24
Dong Y, Wang A. Aberrant DNA methylation in hepatocellular carcinoma tumor suppression (Review). Oncol Lett. 2014;8(3):963–8.
pubmed: 25120642
pmcid: 4114628
doi: 10.3892/ol.2014.2301
Ratti M, Lampis A, Ghidini M, Salati M, Mirchev MB, Valeri N, Hahne JC. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target Oncol. 2020;15(3):261–261.
pubmed: 32451752
pmcid: 7283209
doi: 10.1007/s11523-020-00717-x
Hsu CC, Lee HC, Wei YH. Mitochondrial DNA alterations and mitochondrial dysfunction in the progression of hepatocellular carcinoma. World J Gastroenterol: WJG. 2013;19(47):8880–8880.
pubmed: 24379611
pmcid: 3870539
doi: 10.3748/wjg.v19.i47.8880
Bararia A, Chakraborty P, Roy P, Chattopadhay BK, Das A, Chatterjee A, Sikdar N. Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. World J Gastroenterol. 2023;29(15):2241–2241.
pubmed: 37124888
pmcid: 10134423
doi: 10.3748/wjg.v29.i15.2241
Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, Nolte-‘t Hoen EN, Piper MG, Sivaraman S, Skog J, Théry C, Wauben MH, Hochberg F. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2(1):20360.
doi: 10.3402/jev.v2i0.20360
Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation. 2011;123(10):1116–1116.
pubmed: 21403122
pmcid: 3138723
doi: 10.1161/CIRCULATIONAHA.110.943860
Policy Issues for the Development and Use of Biomarkers in Health. 2011.
Castellani CA, Longchamps RJ, Sun J, Guallar E, Arking DE. Thinking outside the nucleus: Mitochondrial DNA copy number in health and disease. Mitochondrion. 2020;53:214–23.
pubmed: 32544465
pmcid: 7375936
doi: 10.1016/j.mito.2020.06.004
Yalçınkaya B, Tastekin D, Güzelbulut F, Akgoz M, Pençe S. Quantification of cell-free circulating mitochondrial DNA copy number variation in hepatocellular carcinoma. Rev Assoc Med Bras. 2022;68(9):1161–5.
pubmed: 36228247
pmcid: 9575012
doi: 10.1590/1806-9282.20210368
Paolini E, Longo M, Corsini A, Dongiovanni P. The non-invasive assessment of circulating D-loop and mt-ccf levels opens an intriguing spyhole into novel approaches for the Tricky diagnosis of NASH. Int J Mol Sci. 2023;24(3):2331–2331.
pubmed: 36768654
pmcid: 9916898
doi: 10.3390/ijms24032331
He X, Qu F, Zhou F, Zhou X, Chen Y, Guo X, Li J, Huang Q, Yang Y, Lyu Z, Zhang H, Xing J. High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients. Oncotarget. 2016;7(16):22834–22834.
pubmed: 26985767
pmcid: 5008404
doi: 10.18632/oncotarget.8071
Chen N, Wen S, Sun X, et al. Elevated mitochondrial DNA copy number in peripheral blood and tissue predict the opposite outcome of cancer: a meta-analysis. Sci Rep. 2016;6(1):1–11.
Zhou G, Li Y, Li S, Liu H, Xu F, Lai X, Zhang Q, Xu J, Wan S. Circulating cell-free mtDNA content as a non-invasive prognostic biomarker in HCC patients receiving TACE and traditional Chinese medicine. Front genet. 2021;12:1–7.
doi: 10.3389/fgene.2021.719451
Tsoneva DK, Ivanov MN, Vinciguerra M. Liquid Liver biopsy for disease diagnosis and prognosis. 2023.
Li L, Hann HW, Wan S, Hann RS, Wang C, Lai Y, Ye X, Evans A, Myers RE, Ye Z, Li B, Xing J, Yang H. Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. Sci Rep. 2016;6:23992.
pubmed: 27063412
pmcid: 4827061
doi: 10.1038/srep23992
Johnson P, Zhou Q, Dao D, Lo Y. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022;19:670.
pubmed: 35676420
doi: 10.1038/s41575-022-00620-y
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):1–28.
Chi H, Chen D, Zhang Y, Cui Z, Bai Y, Zhang Y. Single-cell transcriptome analysis reveals a cancer-associated fibroblast marker gene signature in hepatocellular carcinoma that predicts prognosis. iLIVER. 2023;2(1):16–25.
doi: 10.1016/j.iliver.2022.12.002
Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, Rheinheimer S, Meder B, Stähler C, Meese E. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016;44(8):3865–77.
pubmed: 26921406
pmcid: 4856985
doi: 10.1093/nar/gkw116
Wang X, Liao Z, Bai Z, He Y, Duan J, Wei L. MiR-93–5p promotes cell proliferation through down-regulating PPARGC1A in Hepatocellular carcinoma cells by bioinformatics analysis and experimental verification. Genes. 2018;9(1):51.
pubmed: 29361788
pmcid: 5793202
doi: 10.3390/genes9010051
Engelmann JC, Amann T, Ott-Rötzer B, Nützel M, Reinders Y, Reinders J, Thasler WE, Kristl T, Teufel A, Huber CG, Oefner PJ, Spang R, Hellerbrand C. Causal modeling of cancer-stromal communication identifies PAPPA as a novel stroma-secreted factor activating NFκB signaling in hepatocellular carcinoma. PLoS Comput Biol. 2015;11(5):e1004293.
pubmed: 26020769
pmcid: 4447342
doi: 10.1371/journal.pcbi.1004293
Kurokawa Y, Matoba R, Takemasa I, Nagano H, Dono K, Nakamori S, Umeshita K, Sakon M, Ueno N, Oba S, Ishii S, Kato K, Monden M. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol. 2004;41(2):284–91.
pubmed: 15288478
doi: 10.1016/j.jhep.2004.04.031
Pirola CJ, Gianotti TF, Burgueño AL, Rey-Funes M, Loidl CF, Mallardi P, San Martino J, Castaño GO, Sookoian S, Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease.
Devall M, Mill J, Lunnon K. The mitochondrial epigenome: a role in Alzheimer’s disease? Epigenomics. 2014;6(6):665–665.
pubmed: 25531259
doi: 10.2217/epi.14.50
Zhang R, Li Y, Yu H, Liu L, Zhu C, Zuo S, Chen Z. An aberrant DNA methylation signature for predicting hepatocellular carcinoma. Ann Transl Med. 2020;8(24):1667–1667.
pubmed: 33490179
pmcid: 7812168
doi: 10.21037/atm-20-7804
Nagashio R, Arai E, Ojima H, Kosuge T, Kondo Y, Kanai Y. Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. Int J Cancer. 2011;129(5):1170–9.
pubmed: 21400512
doi: 10.1002/ijc.26061
Tamura G. Hypermethylation of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. World J Gastrointest Oncol. 2009;1(1):41–41.
pubmed: 21160773
pmcid: 2999099
doi: 10.4251/wjgo.v1.i1.41
Watanabe Y, Maekawa M. Methylation of DNA in cancer. Adv Clin Chem. 2010;52:145–67.
pubmed: 21275343
doi: 10.1016/S0065-2423(10)52006-7
Sheaffer KL, Elliott EN, Kaestner KH. DNA hypomethylation contributes to genomic instability and intestinal cancer initiation. Cancer Prev Res (Philadelphia, Pa). 2016;9(7):534–534.
doi: 10.1158/1940-6207.CAPR-15-0349
Li R, Shui L, Jia J, Wu C. Construction and validation of novel diagnostic and prognostic DNA methylation signatures for hepatocellular carcinoma. Front Genet. 2020. https://doi.org/10.3389/fgene.2020.00906 .
doi: 10.3389/fgene.2020.00906
pubmed: 33763107
pmcid: 7783405
Hlady RA, Zhao X, Pan X, Dong Yang J, Ahmed F, Antwi SO, Giama NH, Patel T, Roberts LR, Liu C, Robertson KD. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. Theranostics. 2019;9(24):7239–7239.
pubmed: 31695765
pmcid: 6831291
doi: 10.7150/thno.35573
Pedersen CA, Cao MD, Fleischer T, Rye MB, Knappskog S, Eikesdal HP, Lønning PE, Tost J, Kristensen VN, Tessem MB, Giskeødegård GF, Bathen TF. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. Breast Cancer Res : BCR. 2022. https://doi.org/10.1186/s13058-022-01537-9 .
doi: 10.1186/s13058-022-01537-9
pubmed: 36369105
pmcid: 9652814
Fernández-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA. Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg. JHEP Rep. 2020;2(6):100167.
pubmed: 33134907
pmcid: 7585149
doi: 10.1016/j.jhepr.2020.100167
Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med. 2019;25(3):403–18.
pubmed: 30842676
doi: 10.1038/s41591-019-0376-8
Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, Lasarte JJ, Pivette P, Trochon-Joseph V, Vasseur B, Dixon G, Sangro B, Sarobe P. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother. 2019;68(3):379–93.
pubmed: 30547218
doi: 10.1007/s00262-018-2283-0
Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma—the SHELTER study. J Hepatol. 2016;65(2):280–8.
pubmed: 26952006
doi: 10.1016/j.jhep.2016.02.043
Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J, Hauptschein R, Rejto PA, Fernandez J, Wang G, Zhang Q, Wang B, Chen R, Wang J, Lee NP, Zhou W, Lin Z, Peng Z, Yi K, Chen S, Li L, Fan X, Yang J, Ye R, Ju J, Wang K, Estrella H, Deng S, Wei P, Qiu M, Wulur IH, Liu J, Ehsani ME, Zhang C, Loboda A, Sung WK, Aggarwal A, Poon RT, Fan ST, Wang J, Hardwick J, Reinhard C, Dai H, Li Y, Luk JM, Mao M. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23(9):1422–33.
pubmed: 23788652
pmcid: 3759719
doi: 10.1101/gr.154492.113
Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, Yu MW, Chen CJ, Santella RM. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology (Baltimore, MD). 2012;55(6):1799–1799.
pubmed: 22234943
doi: 10.1002/hep.25569
Zhang YL, Korsch M, Margetts A, Wahlestedt C, Lohse I. Non-coding RNAs in hepatocellular carcinoma. Livers. 2022;2(3):185–213.
doi: 10.3390/livers2030017
Gupta R, Kleinjans J, Caiment F. Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning. BMC Cancer. 2021;21(1):962.
pubmed: 34445986
pmcid: 8394105
doi: 10.1186/s12885-021-08704-9
Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol: WJG. 2013;19(3):339–339.
pubmed: 23372355
pmcid: 3554817
doi: 10.3748/wjg.v19.i3.339
Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic profiling and artificial intelligence for hepatocellular carcinoma translational medicine. Biomedicines. 2021;9(2):159.
pubmed: 33562077
pmcid: 7914649
doi: 10.3390/biomedicines9020159
Mezzalira S, De Mattia E, Guardascione M, Fratte CD, Cecchin E, Toffoli G. Circulating-free DNA analysis in hepatocellular carcinoma: a promising strategy to improve patients’ management and therapy outcomes. Int J Mol Sci. 2019;20(21):5498.
pubmed: 31694149
pmcid: 6861910
doi: 10.3390/ijms20215498
Lyu X, Tsui YM, Ho DWH, Ng IOL. Liquid biopsy using cell-free or circulating tumor DNA in the management of hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2022;13(6):1611–24.
pubmed: 35183803
pmcid: 9048068
doi: 10.1016/j.jcmgh.2022.02.008
Zhan S, Yang P, Zhou S, Xu Y, Xu R, Liang G, Zhang C, Chen X, Yang L, Jin F, Wang Y. Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis. Front Med. 2022;16(2):216–26.
pubmed: 35416630
doi: 10.1007/s11684-022-0920-7
Wu X, Wang Z, Luo L, Shu D, Wang K. Metabolomics in hepatocellular carcinoma: from biomarker discovery to precision medicine. Front Med Technol. 2022;4:1065506–1065506.
pubmed: 36688143
doi: 10.3389/fmedt.2022.1065506
Childs A, Aidoo-Micah G, Maini MK, Meyer T. Immunotherapy for hepatocellular carcinoma. JHEP Rep. 2024. https://doi.org/10.1016/j.jhepr.2024.101130 .
doi: 10.1016/j.jhepr.2024.101130
pubmed: 39308986
pmcid: 11414669
Nagaraju GP, Dariya B, Kasa P, Peela S, El-Rayes BF. Epigenetics in hepatocellular carcinoma. Semin Cancer Biol. 2022;86:622–32.
pubmed: 34324953
doi: 10.1016/j.semcancer.2021.07.017
Omar MA, Omran MM, Farid K, Tabll AA, Shahein YE, Emran TM, Petrovic A, Lucic NR, Smolic R, Kovac T, Smolic M. Biomarkers for hepatocellular carcinoma: from origin to clinical diagnosis. Biomedicines. 2023;11:1852.
pubmed: 37509493
pmcid: 10377276
doi: 10.3390/biomedicines11071852
Bhan I, Haber DA, Chung RT, Ting DT. Liquid biopsy in hepatocellular carcinoma. Cham: Springer; 2019. p. 125–41.
doi: 10.1007/978-3-030-21540-8_7
Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40–59.
pubmed: 18662800
doi: 10.1016/j.biocel.2008.06.010
Sugiyama Y, Kawakishi S, Osawa T. Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem Pharmacol. 1996;52(4):519–25.
pubmed: 8759023
doi: 10.1016/0006-2952(96)00302-4
Elimam H, Alhamshry NAA, Hatawsh A, Elfar N, Moussa R, Radwan AF, Abd-Elmawla MA, Elkashlan AM, Zaki MB, Abdel-Reheim MA, Mohammed OA, Doghish AS. Natural products and long noncoding RNA signatures in gallbladder cancer: a review focuses on pathogenesis, diagnosis, and drug resistance. Naunyn Schmiedebergs Arch Pharmacol. 2024. https://doi.org/10.1007/s00210-024-03279-1 .
doi: 10.1007/s00210-024-03279-1
pubmed: 39287672
Ralhan R, Pandey MK, Aggarwal BB. Nuclear factor-kappa B links carcinogenic and chemopreventive agents. Front Biosci (Schol Ed). 2009;1(1):45–60.
pubmed: 19482682
doi: 10.2741/s6
Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol. 2005;70(5):700–13.
pubmed: 16023083
doi: 10.1016/j.bcp.2005.04.043
Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther. 2007;6(3):1022–30.
pubmed: 17363495
doi: 10.1158/1535-7163.MCT-06-0545
Shakibaei M, Schulze-Tanzil G, John T, Mobasheri A. Curcumin protects human chondrocytes from IL-l1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: an immunomorphological study. Ann Anat. 2005;187(5–6):487–97.
pubmed: 16320828
doi: 10.1016/j.aanat.2005.06.007
Dai XZ, Yin HT, Sun LF, Hu X, Zhou C, Zhou Y, Zhang W, Huang XE, Li XC. Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev. 2013;14(6):3855–9.
pubmed: 23886196
doi: 10.7314/APJCP.2013.14.6.3855
Wang S, Yu S, Shi W, Ge L, Yu X, Fan J, Zhang J. Curcumin inhibits the migration and invasion of mouse hepatoma Hca-F cells through down-regulating caveolin-1 expression and epidermal growth factor receptor signaling. IUBMB Life. 2011;63(9):775–82.
pubmed: 22362715
doi: 10.1002/iub.507
Chiablaem K, Lirdprapamongkol K, Keeratichamroen S, Surarit R, Svasti J. Curcumin suppresses vasculogenic mimicry capacity of hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition. Anticancer Res. 2014;34(4):1857–64.
pubmed: 24692720
Wang X, Tian Y, Lin H, Cao X, Zhang Z. Curcumin induces apoptosis in human hepatocellular carcinoma cells by decreasing the expression of STAT3/VEGF/HIF-1alpha signaling. Open Life Sci. 2023;18(1):20220618.
pubmed: 37333486
pmcid: 10276545
doi: 10.1515/biol-2022-0618
Gajos-Michniewicz A, Czyz M. WNT/beta-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities. Genes Dis. 2024;11(2):727–46.
pubmed: 37692481
doi: 10.1016/j.gendis.2023.02.050
Hu P, Ke C, Guo X, Ren P, Tong Y, Luo S, He Y, Wei Z, Cheng B, Li R, Luo J, Meng Z. Both glypican-3/Wnt/beta-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma. Dig Liver Dis. 2019;51(1):120–6.
pubmed: 30001951
doi: 10.1016/j.dld.2018.06.012
Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev. 2010;36(1):43–53.
pubmed: 19910122
doi: 10.1016/j.ctrv.2009.10.002
Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, Fokou PVT, Martins N, Sharifi-Rad J. Resveratrol: a double-edged sword in health benefits. Biomedicines. 2018;6(3):91.
pubmed: 30205595
pmcid: 6164842
doi: 10.3390/biomedicines6030091
Singh N, Nigam M, Ranjan V, Zaidi D, Garg VK, Sharma S, Chaturvedi R, Shankar R, Kumar S, Sharma R, Mitra K, Balapure AK, Rath SK. Resveratrol as an adjunct therapy in cyclophosphamide-treated MCF-7 cells and breast tumor explants. Cancer Sci. 2011;102(5):1059–67.
pubmed: 21276137
doi: 10.1111/j.1349-7006.2011.01893.x
Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008;66(8):445–54.
pubmed: 18667005
doi: 10.1111/j.1753-4887.2008.00076.x
Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res. 2008;658(1–2):68–94.
pubmed: 17890139
doi: 10.1016/j.mrrev.2007.08.004
Venturelli S, Berger A, Böcker A, Busch C, Weiland T, Noor S, Leischner C, Schleicher S, Mayer M, Weiss TS, Bischoff SC, Lauer UM, Bitzer M. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS ONE. 2013;8(8):e73097.
pubmed: 24023672
pmcid: 3758278
doi: 10.1371/journal.pone.0073097
Kuo PL, Chiang LC, Lin CC. Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci. 2002;72(1):23–34.
pubmed: 12409142
doi: 10.1016/S0024-3205(02)02177-X
Delmas D, Jannin B, Cherkaoui Malki M, Latruffe N. Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol Rep. 2000;7(4):847–52.
pubmed: 10854556
De Lédinghen V, Monvoisin A, Neaud V, Krisa S, Payrastre B, Bedin C, Desmoulière A, Bioulac-Sage P, Rosenbaum J. Trans-resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells. Int J Oncol. 2001;19(1):83–8.
pubmed: 11408926
Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther. 2005;4(10):1465–74.
pubmed: 16227395
doi: 10.1158/1535-7163.MCT-05-0198
Sun ZJ, Pan CE, Liu HS, Wang GJ. Anti-hepatoma activity of resveratrol in vitro. World J Gastroenterol. 2002;8(1):79–81.
pubmed: 11833076
pmcid: 4656631
doi: 10.3748/wjg.v8.i1.79
Notas G, Nifli AP, Kampa M, Vercauteren J, Kouroumalis E, Castanas E. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta. 2006;1760(11):1657–66.
pubmed: 17052855
doi: 10.1016/j.bbagen.2006.09.010
Yu H, Pan C, Zhao S, Wang Z, Zhang H, Wu W. Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed Pharmacother. 2008;62(6):366–72.
pubmed: 17988825
doi: 10.1016/j.biopha.2007.09.006
Yerian LM, Anders RA, Tretiakova M, Hart J. Caveolin and thrombospondin expression during hepatocellular carcinogenesis. Am J Surg Pathol. 2004;28(3):357–64.
pubmed: 15104298
doi: 10.1097/00000478-200403000-00008
Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001;74(4):418–25.
pubmed: 11566638
doi: 10.1093/ajcn/74.4.418
Ververidis F, Trantas E, Douglas C, Vollmer G, Kretzschmar G, Panopoulos N. Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: Chem Divers, Impacts Plant Biol Human Health, Biotechnol J. 2007;2(10):1214–34.
Cui X, Wang Y, Kokudo N, Fang D, Tang W. Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends. 2010;4(2):39–47.
pubmed: 20448340
Handoussa H, Osmanova N, Ayoub N, Mahran L. Spicatic acid: a 4-carboxygentisic acid from Gentiana spicata extract with potential hepatoprotective activity. Drug Discov Ther. 2009;3(6):278–86.
pubmed: 22495662
Abdel-Salam OM, Youness ER, Mohammed NA, Abd-Elmoniem M, Omara E, Sleem AA. Neuroprotective and hepatoprotective effects of micronized purified flavonoid fraction (Daflon®) in lipopolysaccharide-treated rats. Drug Discov Ther. 2012;6(6):306–14.
pubmed: 23337818
Jiang CP, Ding H, Shi DH, Wang YR, Li EG, Wu JH. Pro-apoptotic effects of tectorigenin on human hepatocellular carcinoma HepG2 cells. World J Gastroenterol. 2012;18(15):1753–64.
pubmed: 22553399
pmcid: 3332288
doi: 10.3748/wjg.v18.i15.1753
Dorn C, Kraus B, Motyl M, Weiss TS, Gehrig M, Scholmerich J, Heilmann J, Hellerbrand C. Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Mol Nutr Food Res. 2010;54(Suppl 2):S205–13.
pubmed: 20087858
Jin J, Chang Y, Wei W, He YF, Hu SS, Wang D, Wu YJ. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro. Acta Pharmacol Sin. 2012;33(5):701–9.
pubmed: 22555372
pmcid: 4010354
doi: 10.1038/aps.2012.13
Sharma A, Upadhyay AK, Bhat MK. Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells. Cancer Biol Ther. 2009;8(22):2106–13.
pubmed: 19901540
doi: 10.4161/cbt.8.22.9687
He W, Li LX, Liao QJ, Liu CL, Chen XL. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication—inducible cell line. World J Gastroenterol. 2011;17(11):1507–14.
pubmed: 21472112
pmcid: 3070027
doi: 10.3748/wjg.v17.i11.1507
Lee JC, Tseng CK, Wu SF, Chang FR, Chiu CC, Wu YC. San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced cyclooxygenase-2 expression. J Viral Hepat. 2011;18(7):e315–24.
pubmed: 21692943
doi: 10.1111/j.1365-2893.2010.01424.x
Zhao J, Chen X, Lin W, Wu G, Zhuang Q, Zhong X, Hong Z, Peng J. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis. Int J Oncol. 2013;42(3):971–8.
pubmed: 23338043
doi: 10.3892/ijo.2013.1779
Hong Z, Chen W, Zhao J, Wu Z, Zhou J, Li T, Hu J. Hepatoprotective effects of Rubus aleaefolius Poir. and identification of its active constituents. J Ethnopharmacol. 2010;129(2):267–72.
pubmed: 20362654
doi: 10.1016/j.jep.2010.03.025
Xue H, Aziz RM, Sun N, Cassady JM, Kamendulis LM, Xu Y, Stoner GD, Klaunig JE. Inhibition of cellular transformation by berry extracts. Carcinogenesis. 2001;22(2):351–6.
pubmed: 11181460
doi: 10.1093/carcin/22.2.351
Lee JH, Ham YA, Choi SH, Im EO, Jung JH, Im KS, Kim DK, Xu Y, Wang MW, Kim ND. Activity of crude extract of Rubus crataegifolius roots as a potent apoptosis inducer and DNA topoisomerase I inhibitor. Arch Pharm Res. 2000;23(4):338–43.
pubmed: 10976580
doi: 10.1007/BF02975444
Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39(11):615–47.
pubmed: 12493639
doi: 10.1016/S0161-5890(02)00252-3
Lin W, Zhao J, Cao Z, Zhuang Q, Zheng L, Cai Q, Chen D, Wang L, Hong Z, Peng J. Livistona chinensis seed suppresses hepatocellular carcinoma growth through promotion of mitochondrial-dependent apoptosis. Oncol Rep. 2013;29(5):1859–66.
pubmed: 23467659
doi: 10.3892/or.2013.2319
Bolhassani A, Khavari A, Bathaie SZ. Saffron and natural carotenoids: Biochemical activities and anti-tumor effects. Biochim Biophys Acta. 2014;1845(1):20–30.
pubmed: 24269582
Bakshi H, Sam S, Rozati R, Sultan P, Islam T, Rathore B, Lone Z, Sharma M, Triphati J, Saxena RC. DNA fragmentation and cell cycle arrest: a hallmark of apoptosis induced by crocin from kashmiri saffron in a human pancreatic cancer cell line. Asian Pac J Cancer Prev. 2010;11(3):675–9.
pubmed: 21039035
Bathaie SZ, Miri H, Mohagheghi MA, Mokhtari-Dizaji M, Shahbazfar AA, Hasanzadeh H. Saffron aqueous extract inhibits the chemically-induced gastric cancer progression in the Wistar albino rat. Iran J Basic Med Sci. 2013;16(1):27–38.
pubmed: 23638290
pmcid: 3637902
Sun Y, Xu HJ, Zhao YX, Wang LZ, Sun LR, Wang Z, Sun XF. Crocin Exhibits Antitumor Effects on Human Leukemia HL-60 Cells In Vitro and In Vivo. Evid Based Complement Alternat Med. 2013;2013:690164.
pubmed: 23573146
pmcid: 3615578
doi: 10.1155/2013/690164
Noureini SK, Wink M. Antiproliferative effects of crocin in HepG2 cells by telomerase inhibition and hTERT down-regulation. Asian Pac J Cancer Prev. 2012;13(5):2305–9.
pubmed: 22901211
doi: 10.7314/APJCP.2012.13.5.2305
Li CY, Huang WF, Wang QL, Wang F, Cai E, Hu B, Du JC, Wang J, Chen R, Cai XJ, Feng J, Li HH. Crocetin induces cytotoxicity in colon cancer cells via p53-independent mechanisms. Asian Pac J Cancer Prev. 2012;13(8):3757–61.
pubmed: 23098467
doi: 10.7314/APJCP.2012.13.8.3757
Adebayo M, Singh S, Singh AP, Dasgupta S. Mitochondrial fusion and fission: the fine-tune balance for cellular homeostasis. Faseb j. 2021;35(6):e21620.
pubmed: 34048084
doi: 10.1096/fj.202100067R
Tseng TH, Chu CY, Huang JM, Shiow SJ, Wang CJ. Crocetin protects against oxidative damage in rat primary hepatocytes. Cancer Lett. 1995;97(1):61–7.
pubmed: 7585479
doi: 10.1016/0304-3835(95)03964-X
Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Hui H, Lu N, Guo QL. Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis. 2013;4(4):e601–e601.
pubmed: 23598413
pmcid: 3641353
doi: 10.1038/cddis.2013.131
Boonnate P, Kariya R, Okada S. Shikonin induces ROS-dependent apoptosis via mitochondria depolarization and ER stress in adult T cell leukemia/lymphoma. Antioxidants. 2023;12:864.
pubmed: 37107239
pmcid: 10135058
doi: 10.3390/antiox12040864
Wiench B, Eichhorn T, Paulsen M, Efferth T. Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells. Evid-Based Complement Altern Med: eCAM. 2012;2012:15–15.
doi: 10.1155/2012/726025
Imam J, Buddavarapu K, Lee-Chang J, Ganapathy S, Camosy C, Chen Y, Rao M. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene. 2010;29(35):4971–9.
pubmed: 20603620
doi: 10.1038/onc.2010.233
Cui Y, Li C, Sang F, Cao W, Qin Z, Zhang P. Natural products targeting glycolytic signaling pathways-an updated review on anti-cancer therapy. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.1035882 .
doi: 10.3389/fphar.2022.1035882
pubmed: 36844911
pmcid: 9815602
Singh M, Kadhim MM, Turki Jalil A, Oudah SK, Aminov Z, Alsaikhan F, Jawhar ZH, Ramírez-Coronel AA, Farhood B. A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity. Cancer Cell Int. 2023;23(1):88.
pubmed: 37165384
pmcid: 10173635
doi: 10.1186/s12935-023-02936-4
Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants. 2015;4(1):204–204.
pubmed: 26785346
pmcid: 4665566
doi: 10.3390/antiox4010204
Shoaib S, Tufail S, Sherwani MA, Yusuf N, Islam N. phenethyl isothiocyanate induces apoptosis through ros generation and caspase-3 activation in cervical cancer cells. Front Pharmacol. 2021;12:673103–673103.
pubmed: 34393773
pmcid: 8358204
doi: 10.3389/fphar.2021.673103
Simon SE, Lim HS, Jayakumar FA, Tan EW, Tan KO. Alpha-mangostin activates MOAP-1 tumor suppressor and mitochondrial signaling in MCF-7 human breast cancer cells. Evid-Based Complement Alternative Med: eCAM. 2022;1:7548191.
El-Far AH, Al Jaouni SK, Li X, Fu J. Cancer metabolism control by natural products: Pyruvate kinase M2 targeting therapeutics. Phytother Res. 2022;36(8):3181–201.
pubmed: 35794729
doi: 10.1002/ptr.7534
Yun SM, Jung JH, Jeong SJ, Sohn EJ, Kim B, Kim SH. Tanshinone IIA induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KBM-5 leukemia cells. Phytother Res. 2014;28(3):458–64.
pubmed: 23813779
doi: 10.1002/ptr.5015
Liao X, Han Y, He Y, Liu J, Wang Y. Natural compounds targeting mitochondrial dysfunction: emerging therapeutics for target organ damage in hypertension. Front Pharmacol. 2023;14:1209890–1209890.
pubmed: 37397478
pmcid: 10311420
doi: 10.3389/fphar.2023.1209890
Chen B, Zhang W, Lin C, Zhang L. A comprehensive review on beneficial effects of catechins on secondary mitochondrial diseases. Int J Mol Sci. 2022;23(19):11569.
pubmed: 36232871
pmcid: 9569714
doi: 10.3390/ijms231911569
Wang L, Song L, Chen X, Suo J, Ma Y, Shi J, Liu K, Chen G. microRNA-139-5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1. CNS Neurosci Ther. 2020;26(4):465–74.
pubmed: 31750616
doi: 10.1111/cns.13268
Meng Q, Li J, Wang C, Shan A. Biological function of resveratrol and its application in animal production: a review. J Animal Sci Biotechnol. 2023;14(1):25–25.
doi: 10.1186/s40104-022-00822-z
A.A. Farooqi, M.Z. Qureshi, S. Khalid, R. Attar, C. Martinelli, Y.S. Uteuliyev, B.N. Sadykov, S. Taverna, P. Poltronieri, B. Xu, Regulation of Cell Signaling Pathways by Berberine in Different Cancers: Searching for Missing Pieces of an Incomplete Jig-Saw Puzzle for an Effective Cancer Therapy, Cancers 11(4) (2019).
Sinha S, Sharma S, Sharma A, Vora J, Shrivastava N. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis. Phytomedicine. 2021;84:153492–153492.
pubmed: 33640782
doi: 10.1016/j.phymed.2021.153492
Coutinho LDL, Junior TCT, Rangel MC. Sulforaphane: an emergent anti-cancer stem cell agent. Front Oncol. 2023;13:1089115.
pubmed: 36776295
pmcid: 9909961
doi: 10.3389/fonc.2023.1089115
Mondal P, Meeran SM, Dietary regulation of miRNA in precision medicine of lung cancer, epigenetics in precision medicine. 2021 pp. 513–542.
Cismowski MJ, Genistein, xPharm: the comprehensive pharmacology reference. 2007 pp. 1–7.
Kim GT, Lee SH, Kim JI, Kim YM. Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway and induces apoptosis by increasing the generation of intracellular ROS in a p53-independent manner. Int J Mol Med. 2014;33(4):863–9.
pubmed: 24535669
pmcid: 3976123
doi: 10.3892/ijmm.2014.1658
Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen M, Wang Y. Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma. J Ethnopharmacol. 2013;149(3):601–12.
pubmed: 23916858
doi: 10.1016/j.jep.2013.07.030
Zhang Y, Huang H, Jin L, Lin S. Anticarcinogenic effects of isothiocyanates on hepatocellular carcinoma. Int J Mol Sci. 2022;23(22):13834.
pubmed: 36430307
pmcid: 9693344
doi: 10.3390/ijms232213834
Ting CT, Li WC, Chen CY, Tsai TH. Preventive and therapeutic role of traditional Chinese herbal medicine in hepatocellular carcinoma. J Chin Med Assoc. 2015;78(3):139–44.
pubmed: 25447209
doi: 10.1016/j.jcma.2014.09.003
Mandlik DS, Mandlik SK. Herbal and natural dietary products: upcoming therapeutic approach for prevention and treatment of hepatocellular carcinoma. Nutr Cancer. 2021;73(11–12):2130–54.
pubmed: 33073617
doi: 10.1080/01635581.2020.1834591
Rahman M, Almalki WH, Alrobaian M, Iqbal J, Alghamdi S, Alharbi KS, Alruwaili NK, Hafeez A, Shaharyar A, Singh T, Waris M, Kumar V, Beg S. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opin Drug Deliv. 2021;18(4):489–513.
pubmed: 33225771
doi: 10.1080/17425247.2021.1854223
Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103–19.
pubmed: 25205159
doi: 10.1016/j.pharmthera.2014.09.005
Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol. 2007;13(40):5299–305.
pubmed: 17879397
pmcid: 4171317
doi: 10.3748/wjg.v13.i40.5299
Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem. 2010;21(2):140–6.
pubmed: 19269153
doi: 10.1016/j.jnutbio.2008.12.003
Murugan RS, Vinothini G, Hara Y, Nagini S. Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model. Anticancer Res. 2009;29(6):2301–5.
pubmed: 19528495
Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L, Chen GG, Yun J. Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo. PLoS ONE. 2012;7(6):e39870.
pubmed: 22761917
pmcid: 3386188
doi: 10.1371/journal.pone.0039870
Wu L, Li J, Liu T, Li S, Feng J, Yu Q, Zhang J, Chen J, Zhou Y, Ji J, Chen K, Mao Y, Wang F, Dai W, Fan X, Wu J, Guo C. Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway. Cancer Med. 2019;8(10):4806–20.
pubmed: 31273958
pmcid: 6712453
doi: 10.1002/cam4.2388
Majdalawieh AF, Fayyad MW. Recent advances on the anti-cancer properties of Nigella sativa, a widely used food additive. J Ayurveda Integr Med. 2016;7(3):173–80.
pubmed: 27649635
pmcid: 5052360
doi: 10.1016/j.jaim.2016.07.004
Khan F, Kalamegam G, Gari M, Abuzenadah A, Chaudhary A, Al Qahtani M, Al Ghamdi K, Jamal T, Al Malki A, Kumosani T. Evaluation of the effect of Nigella sativa extract on human hepatocellular adenocarcinoma cell line (HepG2) in vitro. BMC Genomics. 2014;15:1.
doi: 10.1186/1471-2164-15-S2-P63
Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR Jr, Thiele JJ, Grindle SM, Bliss RL, Skubitz AP. Differential gene expression in ovarian carcinoma. Am J Pathol. 2004;165(2):397–414.
pubmed: 15277215
pmcid: 1618570
doi: 10.1016/S0002-9440(10)63306-8
Ji BC, Hsu WH, Yang JS, Hsia TC, Lu CC, Chiang JH, Yang JL, Lin CH, Lin JJ, Suen LJ, Gibson Wood W, Chung JG. Gallic acid induces apoptosis via caspase-3 and mitochondrion-dependent pathways in vitro and suppresses lung xenograft tumor growth in vivo. J Agric Food Chem. 2009;57(16):7596–604.
pubmed: 20349925
doi: 10.1021/jf901308p
Tan W, Li Y, Chen M, Wang Y. Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomed. 2011;6:1773–7.
doi: 10.2147/IJN.S22683
Wang XN, Han X, Xu LN, Yin LH, Xu YW, Qi Y, Peng JY. Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine. Phytomedicine. 2008;15(12):1062–8.
pubmed: 18579357
doi: 10.1016/j.phymed.2008.05.002
Hwang JM, Kuo HC, Tseng TH, Liu JY, Chu CY. Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch Toxicol. 2006;80(2):62–73.
pubmed: 16189662
doi: 10.1007/s00204-005-0014-8
Matilainen O, Quirós PM, Auwerx J. Mitochondria and epigenetics—crosstalk in homeostasis and stress. Trends Cell Biol. 2017;27(6):453–63.
pubmed: 28274652
doi: 10.1016/j.tcb.2017.02.004
Chatterjee D, Das P, Chakrabarti O. Mitochondrial epigenetics regulating inflammation in cancer and aging. Front Cell Dev Biol. 2022;10:929708.
pubmed: 35903542
pmcid: 9314556
doi: 10.3389/fcell.2022.929708
Gao S, Tian X, Chang H, Sun Y, Wu Z, Cheng Z, Dong P, Zhao Q, Ruan J, Bu W. Two novel lncRNAs discovered in human mitochondrial DNA using PacBio full-length transcriptome data. Mitochondrion. 2018;38:41–7.
pubmed: 28802668
doi: 10.1016/j.mito.2017.08.002
Wakae K, Nishiyama T, Kondo S, Izuka T, Que L, Chen C, Kase K, Kitamura K, Mohiuddin M, Wang Z, Ahasan MM, Nakamura M, Fujiwara H, Yoshizaki T, Hosomochi K, Tajima A, Nakahara T, Kiyono T, Muramatsu M. Keratinocyte differentiation induces APOBEC3A, 3B, and mitochondrial DNA hypermutation. Sci Rep. 2018;8(1):9745.
pubmed: 29950685
pmcid: 6021414
doi: 10.1038/s41598-018-27930-z
Elimam H, Moussa R, Radwan AF, Hatawsh A, Elfar N, Alhamshry NAA, Abd-Elmawla MA, Aborehab NM, Zaki MB, Mageed SSA, Mohammed OA, Abdel-Reheim MA, Doghish AS. LncRNAs orchestration of gastric cancer - particular emphasis on the etiology, diagnosis, and treatment resistance. Funct Integr Genomics. 2024;24(5):175.
pubmed: 39325107
doi: 10.1007/s10142-024-01450-8
Doghish AS, Zaki MB, Eldeib MG, Radwan AF, Moussa R, Abdel-Wahab MM, Kizilaslan EZ, Alhamshry NAA, Ashour AE, Elimam H. The potential relevance of long non-coding RNAs in colorectal cancer pathogenesis and treatment: a review focus on signaling pathways. Pathol Res Pract. 2024;253:155044.
pubmed: 38141573
doi: 10.1016/j.prp.2023.155044
Hauser AT, Robaa D, Jung M. Epigenetic small molecule modulators of histone and DNA methylation. Curr Opin Chem Biol. 2018;45:73–85.
pubmed: 29579619
doi: 10.1016/j.cbpa.2018.03.003
Mohammed SA, Ambrosini S, Lüscher T, Paneni F, Costantino S. Epigenetic control of mitochondrial function in the vasculature. Front Cardiovasc Med. 2020;7:28.
pubmed: 32195271
pmcid: 7064473
doi: 10.3389/fcvm.2020.00028
Sun W, Lu Y, Zhang H, Zhang J, Fang X, Wang J, Li M. Mitochondrial non-coding rnas are potential mediators of mitochondrial homeostasis. Biomolecules. 2022;12(12):1863.
pubmed: 36551291
pmcid: 9775270
doi: 10.3390/biom12121863
Nicolson GL. Mitochondrial dysfunction and chronic disease: treatment with natural supplements. Integr Med (Encinitas). 2014;13(4):35–43.
pubmed: 26770107
Xue C, Gu X, Li G, Bao Z, Li L. Mitochondrial Mechanisms of Necroptosis in Liver Diseases. Int J Mol Sci. 2020;22(1):66.
pubmed: 33374660
pmcid: 7793526
doi: 10.3390/ijms22010066
Zhang C, Zhao Y, Yu M, Qin J, Ye B, Wang Q. Mitochondrial Dysfunction and Chronic Liver Disease. Curr Issues Mol Biol. 2022;44(7):3156–65.
pubmed: 35877442
pmcid: 9319137
doi: 10.3390/cimb44070218
Doblado L, Lueck C, Rey C, Samhan-Arias AK, Prieto I, Stacchiotti A, Monsalve M. Mitophagy in human diseases. Int J Mol Sci. 2021;22(8):3903.
pubmed: 33918863
pmcid: 8069949
doi: 10.3390/ijms22083903
Dominy JE Jr, Lee Y, Gerhart-Hines Z, Puigserver P. Nutrient-dependent regulation of PGC-1alpha’s acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5. Biochim Biophys Acta. 2010;1804(8):1676–83.
pubmed: 20005308
doi: 10.1016/j.bbapap.2009.11.023
LeBleu VS, O’Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, Asara JM, Kalluri R. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16(10):992–1003.
pubmed: 25241037
pmcid: 4369153
doi: 10.1038/ncb3039
Li Y, Xu S, Li J, Zheng L, Feng M, Wang X, Han K, Pi H, Li M, Huang X, You N, Tian Y, Zuo G, Li H, Zhao H, Deng P, Yu Z, Zhou Z, Liang P. SIRT1 facilitates hepatocellular carcinoma metastasis by promoting PGC-1α-mediated mitochondrial biogenesis. Oncotarget. 2016;7(20):29255–74.
pubmed: 27081083
pmcid: 5045394
doi: 10.18632/oncotarget.8711
Zuo Q, He J, Zhang S, Wang H, Jin G, Jin H, Cheng Z, Tao X, Yu C, Li B, Yang C, Wang S, Lv Y, Zhao F, Yao M, Cong W, Wang C, Qin W. PPARγ coactivator-1α suppresses metastasis of hepatocellular carcinoma by inhibiting warburg effect by PPARγ-dependent WNT/β-catenin/pyruvate dehydrogenase kinase isozyme 1 axis. Hepatology. 2021;73(2):644–60.
pubmed: 32298475
doi: 10.1002/hep.31280
Yin PH, Lee HC, Chau GY, Wu YT, Li SH, Lui WY, Wei YH, Liu TY, Chi CW. Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer. 2004;90(12):2390–6.
pubmed: 15150555
pmcid: 2409531
doi: 10.1038/sj.bjc.6601838
Lee HC, Yin PH, Lin JC, Wu CC, Chen CY, Wu CW, Chi CW, Tam TN, Wei YH. Mitochondrial genome instability and mtDNA depletion in human cancers. Ann N Y Acad Sci. 2005;1042:109–22.
pubmed: 15965052
doi: 10.1196/annals.1338.011
Yamada S, Nomoto S, Fujii T, Kaneko T, Takeda S, Inoue S, Kanazumi N, Nakao A. Correlation between copy number of mitochondrial DNA and clinico-pathologic parameters of hepatocellular carcinoma. Eur J Surg Oncol. 2006;32(3):303–7.
pubmed: 16478656
doi: 10.1016/j.ejso.2006.01.002
Zhao S, Yang Y, Liu J, Liu H, Ge N, Yang H, Zhang H, Xing J. Association of mitochondrial DNA content in peripheral blood leukocyte with hepatitis B virus-related hepatocellular carcinoma in a Chinese Han population. Cancer Sci. 2011;102(8):1553–8.
pubmed: 21521418
doi: 10.1111/j.1349-7006.2011.01968.x
Hashad DI, Elyamany AS, Salem PE. Mitochondrial dna copy number in egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Genet Test Mol Biomarkers. 2015;19(11):604–9.
pubmed: 26447820
doi: 10.1089/gtmb.2015.0132
Mitra K. Mitochondrial fission-fusion as an emerging key regulator of cell proliferation and differentiation. BioEssays. 2013;35(11):955–64.
pubmed: 23943303
doi: 10.1002/bies.201300011
Lima AR, Santos L, Correia M, Soares P, Sobrinho-Simões M, Melo M, Máximo V. Dynamin-related protein 1 at the crossroads of cancer. Genes (Basel). 2018;9(2):115.
pubmed: 29466320
doi: 10.3390/genes9020115
Zhan L, Cao H, Wang G, Lyu Y, Sun X, An J, Wu Z, Huang Q, Liu B, Xing J. Drp1-mediated mitochondrial fission promotes cell proliferation through crosstalk of p53 and NF-κB pathways in hepatocellular carcinoma. Oncotarget. 2016;7(40):65001–11.
pubmed: 27542250
pmcid: 5323133
doi: 10.18632/oncotarget.11339
Yi T, Luo H, Qin F, Jiang Q, He S, Wang T, Su J, Song S, Qin X, Qin Y, Zhou X, Huang Z. LncRNA LL22NC03-N14H11.1 promoted hepatocellular carcinoma progression through activating MAPK pathway to induce mitochondrial fission. Cell Death Dis. 2020;11(10):832.
pubmed: 33028809
pmcid: 7542152
doi: 10.1038/s41419-020-2584-z
Sun X, Cao H, Zhan L, Yin C, Wang G, Liang P, Li J, Wang Z, Liu B, Huang Q, Xing J. Mitochondrial fission promotes cell migration by Ca(2+) /CaMKII/ERK/FAK pathway in hepatocellular carcinoma. Liver Int. 2018;38(7):1263–72.
pubmed: 29210177
doi: 10.1111/liv.13660
Lin X-H, Qiu B-Q, Ma M, Zhang R, Hsu S-J, Liu H-H, Chen J, Gao D-M, Cui J-F, Ren Z-G, Chen R-X. Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia. Oncogenesis. 2020;9(7):67.
pubmed: 32661251
pmcid: 7359348
doi: 10.1038/s41389-020-00251-5
Zhang Y, Li H, Chang H, Du L, Hai J, Geng X, Yan X. MTP18 overexpression contributes to tumor growth and metastasis and associates with poor survival in hepatocellular carcinoma. Cell Death Dis. 2018;9(10):956.
pubmed: 30237394
pmcid: 6148245
doi: 10.1038/s41419-018-0987-x
Srinivasan S, Guha M, Kashina A, Avadhani NG. Mitochondrial dysfunction and mitochondrial dynamics-the cancer connection. Biochim Biophys Acta Bioenerg. 2017;1858(8):602–14.
pubmed: 28104365
doi: 10.1016/j.bbabio.2017.01.004
Wang W, Xie Q, Zhou X, Yao J, Zhu X, Huang P, Zhang L, Wei J, Xie H, Zhou L, Zheng S. Mitofusin-2 triggers mitochondria Ca2+ influx from the endoplasmic reticulum to induce apoptosis in hepatocellular carcinoma cells. Cancer Lett. 2015;358(1):47–58.
pubmed: 25541060
doi: 10.1016/j.canlet.2014.12.025
Hernández-Alvarez MI, Sebastián D, Vives S, Ivanova S, Bartoccioni P, Kakimoto P, Plana N, Veiga SR, Hernández V, Vasconcelos N, Peddinti G, Adrover A, Jové M, Pamplona R, Gordaliza-Alaguero I, Calvo E, Cabré N, Castro R, Kuzmanic A, Boutant M, Sala D, Hyotylainen T, Orešič M, Fort J, Errasti-Murugarren E, Rodrígues CMP, Orozco M, Joven J, Cantó C, Palacin M, Fernández-Veledo S, Vendrell J, Zorzano A. Deficient endoplasmic reticulum-mitochondrial phosphatidylserine transfer causes liver disease. Cell. 2019;177(4):881-895.e17.
pubmed: 31051106
doi: 10.1016/j.cell.2019.04.010
Zhang Z, Li TE, Chen M, Xu D, Zhu Y, Hu BY, Lin ZF, Pan JJ, Wang X, Wu C, Zheng Y, Lu L, Jia HL, Gao S, Dong QZ, Qin LX. MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming. Br J Cancer. 2020;122(2):209–20.
pubmed: 31819189
doi: 10.1038/s41416-019-0658-4
Cipolat S, Rudka T, Hartmann D, Costa V, Serneels L, Craessaerts K, Metzger K, Frezza C, Annaert W, D’Adamio L, Derks C, Dejaegere T, Pellegrini L, D’Hooge R, Scorrano L, De Strooper B. Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell. 2006;126(1):163–75.
pubmed: 16839884
doi: 10.1016/j.cell.2006.06.021
Li M, Wang L, Wang Y, Zhang S, Zhou G, Lieshout R, Ma B, Liu J, Qu C, Verstegen MMA, Sprengers D, Kwekkeboom J, van der Laan LJW, Cao W, Peppelenbosch MP, Pan Q. Mitochondrial fusion via OPA1 and MFN1 supports liver tumor cell metabolism and growth. Cells. 2020;9(1):121.
pubmed: 31947947
pmcid: 7017104
doi: 10.3390/cells9010121
Ke PY. Mitophagy in the pathogenesis of liver diseases. Cells. 2020;9(4):831.
pubmed: 32235615
pmcid: 7226805
doi: 10.3390/cells9040831
Xu W, Zhao D, Huang X, Zhang M, Yin M, Liu L, Wu H, Weng Z, Xu C. The prognostic value and clinical significance of mitophagy-related genes in hepatocellular carcinoma. Front Genet. 2022;13:917584.
pubmed: 35991574
pmcid: 9388833
doi: 10.3389/fgene.2022.917584
Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112(12):1809–20.
pubmed: 14638851
pmcid: 297002
doi: 10.1172/JCI20039
Chi HC, Chen SL, Lin SL, Tsai CY, Chuang WY, Lin YH, Huang YH, Tsai MM, Yeh CT, Lin KH. Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover. Oncogene. 2017;36(37):5274–84.
pubmed: 28504722
doi: 10.1038/onc.2017.136
Liu Z, Ren B, Wang Y, Zou C, Qiao Q, Diao Z, Mi Y, Zhu D, Liu X. Sesamol Induces human hepatocellular carcinoma cells apoptosis by impairing mitochondrial function and suppressing autophagy. Sci Rep. 2017;7(1):45728.
pubmed: 28374807
pmcid: 5379556
doi: 10.1038/srep45728
Liu K, Lee J, Kim JY, Wang L, Tian Y, Chan ST, Cho C, Machida K, Chen D, Ou JJ. Mitophagy controls the activities of tumor suppressor p53 to regulate hepatic cancer stem cells. Mol Cell. 2017;68(2):281-292.e5.
pubmed: 29033320
pmcid: 5687282
doi: 10.1016/j.molcel.2017.09.022
Qian H, Chao X, Ding WX. A PINK1-mediated mitophagy pathway decides the fate of tumors-to be benign or malignant? Autophagy. 2018;14(4):563–6.
pubmed: 29313453
pmcid: 5959334
doi: 10.1080/15548627.2018.1425057
Ma X, McKeen T, Zhang J, Ding W-X. Role and mechanisms of mitophagy in liver diseases. Cells. 2020;9(4):837.
pubmed: 32244304
pmcid: 7226762
doi: 10.3390/cells9040837
Shidara Y, Yamagata K, Kanamori T, Nakano K, Kwong JQ, Manfredi G, Oda H, Ohta S. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res. 2005;65(5):1655–63.
pubmed: 15753359
doi: 10.1158/0008-5472.CAN-04-2012
Lee HY, Nga HT, Tian J, Yi HS. Mitochondrial metabolic signatures in hepatocellular carcinoma. Cells. 2021;10(8):1901.
pubmed: 34440674
pmcid: 8391498
doi: 10.3390/cells10081901
Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY, Yoo NJ. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol. 2001;32(3):250–6.
pubmed: 11274632
doi: 10.1053/hupa.2001.22769
Cheng J, Qian D, Ding X, Song T, Cai M, Dan X, Wang Y, Zhao J, Liu Z, Wu Z, Pang Q, Zhu L, Wang P, Hao X, Yuan Z. High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients. Cell Death Dis. 2018;9(10):991.
pubmed: 30250224
pmcid: 6155280
doi: 10.1038/s41419-018-1017-8
Li J, Jiang R, Cong X, Zhao Y. UCP2 gene polymorphisms in obesity and diabetes, and the role of UCP2 in cancer. FEBS Lett. 2019;593(18):2525–34.
pubmed: 31330574
doi: 10.1002/1873-3468.13546
Lozano-Rosas M, Chavez E, Aparicio-Cadena A, Velasco-Loyden G, Sánchez V. Mitoepigenetics and hepatocellular carcinoma. Hepatoma Research. 2018;4:19.
doi: 10.20517/2394-5079.2018.48
Malik AN, Czajka A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion. 2013;13(5):481–92.
pubmed: 23085537
doi: 10.1016/j.mito.2012.10.011
Ferreira A, Serafim TL, Sardão VA, Cunha-Oliveira T. Role of mtDNA-related mitoepigenetic phenomena in cancer. Eur J Clin Invest. 2015;45(Suppl 1):44–9.
pubmed: 25524586
doi: 10.1111/eci.12359
Ye C, Tao R, Cao Q, Zhu D, Wang Y, Wang J, Lu J, Chen E, Li L. Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma. Int J Oncol. 2016;49(2):589–602.
pubmed: 27221337
doi: 10.3892/ijo.2016.3535
Shen F, Huang W, Qi JH, Yuan BF, Huang JT, Zhou X, Feng YQ, Liu YJ, Liu SM. Association of 5-methylcytosine and 5-hydroxymethylcytosine with mitochondrial DNA content and clinical and biochemical parameters in hepatocellular carcinoma. PLoS ONE. 2013;8(10):e76967.
pubmed: 24143196
pmcid: 3797098
doi: 10.1371/journal.pone.0076967
Xie CH, Naito A, Mizumachi T, Evans TT, Douglas MG, Cooney CA, Fan CY, Higuchi M. Mitochondrial regulation of cancer associated nuclear DNA methylation. Biochem Biophys Res Commun. 2007;364(3):656–61.
pubmed: 17964537
pmcid: 2443723
doi: 10.1016/j.bbrc.2007.10.047
Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers (Basel). 2020;12(2):491.
pubmed: 32093152
doi: 10.3390/cancers12020491
Bouattour M, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, Faivre S. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67(3):1132–49.
pubmed: 28862760
doi: 10.1002/hep.29496
Luo T, Zhang SG, Zhu LF, Zhang FX, Li W, Zhao K, Wen XX, Yu M, Zhan YQ, Chen H, Ge CH, Gao HY, Wang L, Yang XM, Li CY. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019;38(1):130.
pubmed: 30885237
pmcid: 6421704
doi: 10.1186/s13046-019-1104-4
Gao F, Deng G, Liu W, Zhou K, Li M. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway. Oncol Rep. 2017;37(2):1203–11.
pubmed: 28075467
doi: 10.3892/or.2017.5347
Elimam H, Eldeib MG, Kizilaslan EZ, Alhamshry NAA, Ashour AE, Elfar N, Abdel-Wahab MM, Zaki MB, Mohammed OA, Radwan AF, Abdel-Reheim MA, Moussa R, Doghish AS. Exploring the interplay of natural products and long non-coding RNAs in colorectal cancer: pathogenesis, diagnosis, and overcoming drug resistance. Naunyn Schmiedebergs Arch Pharmacol. 2024. https://doi.org/10.1007/s00210-024-03425-9 .
doi: 10.1007/s00210-024-03425-9
pubmed: 39287672
Yamada N, Matsushima-Nishiwaki R, Kozawa O. Quercetin suppresses the migration of hepatocellular carcinoma cells stimulated by hepatocyte growth factor or transforming growth factor-α: attenuation of AKT signaling pathway. Arch Biochem Biophys. 2020;682:108296.
pubmed: 32032576
doi: 10.1016/j.abb.2020.108296
Ko H, Huh G, Jung SH, Kwon H, Jeon Y, Park YN, Kim YJ. Diospyros kaki leaves inhibit HGF/Met signaling-mediated EMT and stemness features in hepatocellular carcinoma. Food Chem Toxicol. 2020;142:111475.
pubmed: 32522589
doi: 10.1016/j.fct.2020.111475
Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL, Mihu CM. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–67.
pubmed: 30173249
Hamdy M, Shaheen K, Awad M, Barakat E, Shalaby S, Gupta N, Gupta V, Shahu C. Vascular endothelial growth factor (VEGF) as a biochem- ical marker for the diagnosis of hepatocellular carcinoma (HCC). Clin Pract. 2020;17:1441–53.
Mabeta P, Steenkamp V. The VEGF/VEGFR axis revisited: implications for cancer therapy. Int J Mol Sci. 2022;23(24):15585.
pubmed: 36555234
pmcid: 9779738
doi: 10.3390/ijms232415585
Chen Y, Zhong W, Chen B, Yang C, Zhou S, Liu J. Effect of curcumin on vascular endothelial growth factor in hypoxic HepG2 cells via the insulin-like growth factor 1 receptor signaling pathway. Exp Ther Med. 2018;15(3):2922–8.
pubmed: 29599831
pmcid: 5867490
Pan Z, Zhuang J, Ji C, Cai Z, Liao W, Huang Z. Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression. Oncol Lett. 2018;15(4):4821–6.
pubmed: 29552121
pmcid: 5840714
Liao ZH, Zhu HQ, Chen YY, Chen RL, Fu LX, Li L, Zhou H, Zhou JL, Liang G. The epigallocatechin gallate derivative Y(6) inhibits human hepatocellular carcinoma by inhibiting angiogenesis in MAPK/ERK1/2 and PI3K/AKT/ HIF-1α/VEGF dependent pathways. J Ethnopharmacol. 2020;259:112852.
pubmed: 32278759
doi: 10.1016/j.jep.2020.112852
Ren F, Wu K, Yang Y, Yang Y, Wang Y, Li J. Dandelion polysaccharide exerts anti-angiogenesis effect on hepatocellular carcinoma by regulating VEGF/HIF-1α expression. Front Pharmacol. 2020;11:460.
pubmed: 32322211
pmcid: 7158757
doi: 10.3389/fphar.2020.00460